Investorideas.com Security Conference Adds Viscount Systems (OTCQB

VSYS) to Presenters; Speakers Discuss Key Security Issues Including Biodefense, Biometrics and Cybersecurity - Seite 2

"Biometric technology is advancing faster than many people realize. The consumer and mobile spaces have seen huge gains in the past year, bringing authentication and payment systems to the forefront of this discussion. All the while, security and defense applications are more technologically advanced today than they ever have been and international adoption is soaring." -- Adam Vrankulj, Managing Editor, BiometricUpdate.com.

New speakers added:
Manish Thakur, Managing Partner of Hudson Fairfax Group
Manish Thakur is Managing Partner of Hudson Fairfax Group, a strategic investment firm based in New York, Washington and London, focused on cybersecurity, intelligence, big data analytics, and defense private equity. Manish has spent over 20 years covering defense, technology, telecommunications and satellite companies as a principal investor, CFO and investment banker. Before founding HFG, he worked at such firms as Merrill Lynch, SG Cowen and HSBC, where his responsibilities included private equity and strategic investments, initial public offerings, and mergers and acquisitions. Manish also serves as National Security Coordinator for a Capitol Hill-based political action committee. Manish holds an MBA in Finance from Columbia University Graduate School of Business, and a BSc (honors) in Economics from the University of London.

Jason Kolbert, Head of Healthcare Research, Senior Managing Director and Biotechnology Analyst, Maxim Group
Jason's career began as a chemist in the pharmaceutical industry, and evolved into a product, and marketing manager with Schering-Plough in Japan. Upon returning from Japan, Jason joined Salomon Smith Barney, as a research associate which has now evolved into an 18 year career on Wall Street as a ranked biotechnology analyst.

Mr. Kolbert today is a senior managing director with the Maxim group and the head of Healthcare Research as well as a covering analyst. As the head of Healthcare, Jason manages the Healthcare effort to maintain a balance of large capitalized relevant institutional coverage combined with the next generation of small capitalized emerging companies that will influence the sector. As a covering analyst Mr. Kolbert's focus is across several therapeutic areas with an emphasis in antiviral medicine, regenerative medicine, oncology and immunology (cell therapy). Mr. Kolbert is noted for being among the first analysts to focus on the changing landscape for Hepatitis C therapy, identifying Pharmasset in its early days as a company with paradigm shifting nucleoside technology (subsequently acquired by Gilead for $11 billion). Today Mr. Kolbert is making the same call for Stem Cell Therapy, identifying the sector as having the potential to alter current treatment paradigms.